Biogen is in the sights of giants like Merck and Allergan. According to rumors reported by the Wall Street Journal, Merck and Allergan they would have raised the possibility of an acquisition of the US biotechnology group. Negotiations are at an early stage.
If it happens, it’d be the biggest deal since 2008 when Roche acquired Genentech. Representatives from Merck and Biogen did not immediately respond to request for comment. Allergan declined to comment.
The "Ice Bucket Challenge" was a social media sensation in the summer of 2014, with people across the world dumping cold water on themselves to raise money and awareness for ALS – amyotrophic lateral sclerosis, which is also known as Lou Gehrig’s disease.
But in the last hours the famous initiative has been able to produce something even more concrete because, as reported from the ALS Association, one of the research projects funded through the initiative has resulted in a remarkable discovery in the fight against ALS: the scientists of Project MinE for gene sequencing have identified a new ALS gene, NEK1, which is now considered one of the most common genes that contribute to disease. This will provide scientists a new potential target for the development of therapies.
For qualified investors / professional clients only
In order to proceed, you must confirm that you are a qualified investor based in Switzerland
The information contained in this section have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document.
Before investing in a product please read the latest prospectus carefully and thoroughly and note that funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided without any guarantee or warranty and are for the recipient's personal use and information purposes only
